Publications
457 publications
- Date
- Relevance
-
12 SQ-HDM SLIT (Itulazax®) for the treatment of allergic rhinitis or conjunctivitis induced by pollen from the birch homologous group
The National Health Care Institute has completed its assessment whether 12 SQ-HDM SLIT (Itulazax®) is interchangeable with a ...
-
Asfotase alfa (Strensiq ®) for the treatment of hypophosphatasia (HPP)
The National Health Care Institute has completed its assessment whether asfotase alfa (Strensiq®) is interchangeable with a ...
-
Olaparib (Lynparza®) for the maintenance treatment of adult patients with carcinoma of the ovaries, tubes or peritoneum
The National Health Care Institute has completed its assessment whether olaparib (Lynparza®) as a monotherapy for the maintenance ...
-
Trientine tetrahydrochloride (Cuprior®) the treatment of Wilson’s disease
The National Health Care Institute has completed its assessment whether trientine tetrahydrochloride (Cuprior®) is ...
-
Hydroquinine (Inhibin®) for patients with nocturnal muscle cramps
The National Health Care Institute has assessed whether hydroquinine (Inhibin®) should be included in the medication ...
-
Voretigene neparvovec (Luxturna®) for the treatment of vision loss due to inherited retinal dystrophy with bi-allelic RPE65 mutations
The National Health Care Institute has completed its assessment whether voretigene neparvovec (Luxturna®) for the treatment of ...
-
Emicizumab (Hemlibra®) for the prophylactic treatment of bleeding in patients with severe haemophilia A without inhibitors
The National Health Care Institute has completed its assessment whether emicizumab (Hemlibra®) for the prophylactic treatment of ...
-
GVS assessment of Bevespi® aerosphere for the treatment of COPD
The National Health Care Institute has completed its assessment whether Bevespi® aerosphere for the treatment of COPD, can be ...
-
GVS assessment of racecadotril (Hidrasec®) for the treatment of acute diarrhoea in infants (over 3 months of age) and children
The National Health Care Institute has completed its assessment whether racecadotril (Hidrasec®) is interchangeable with another ...
-
GVS assessment of a 4 component meningococcal B vaccine (Bexsero®)
The National Health Care Institute has completed its assessment whether the product 4 component meningococcal B vaccine (4CMenB) ...